Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.

Madrigal Pharmaceuticals MDGL shares soared 10.9% on Wednesday. The uptrend was observed after the U.S. Patent and Trademark ...

Proceeds to primarily support MASH pipeline expansion and to refinance existing senior credit facility <li /> $350 million initial term ...

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) saw its stock climb 6.1% following the announcement that the U.S. Patent and Trademark Office has issued a Notice of Allowance for its MASH treatment, ...

Madrigal Pharmaceuticals (NASDAQ: MDGL), a mid-cap company, might have as decent a shot at becoming as prominent in the field as most of its similarly sized peers.

Madrigal Pharmaceuticals earned an important regulatory approval this year. However, the biotech faces risks, including the need for a post-marketing study. While the new medicine has good ...

Madrigal Pharmaceuticals sought to secure $500 million through a public offering comprising 1.25 million common shares priced at $151.69 each and pre-funded warrants for an additional 2.05 million ...

Read about Madrigal Pharmaceuticals Inc (MDGL:XNAS) stock and today's latest news and financial updates.

Madrigal Pharmaceuticals Inc has a consensus price target of $379.5 based on the ratings of 16 analysts. The high is $469 issued by Citigroup on February 27, 2025.

With shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) up by 220% over the last three years, it's easy to see why investors might get the idea that there isn't much upside left with this biotech ...

Madrigal Pharmaceuticals Inc. Madrigal Pharmaceuticals Inc MDGL. Stock XNAS Rating as of Jul 17, 2025. Download PDF. More Actions Summary; Chart; News; Price vs Fair Value; Sustainability; ...

Madrigal Pharmaceuticals (MDGL-0.55%), a mid-cap company, might have as decent a shot at becoming as prominent in the field as most of its similarly sized peers.